drugset / Trial / NCT07467629
QLS5212 for Participants With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.
Timeline
- Start
- 2026-05-11
- Primary completion
- 2027-11-05
- Completion
- 2028-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS5212 | Unknown | — | Intravenous |
Indications
No indication recorded.